Nivalis Therapeutics, Inc. (ALPN)
(Delayed Data from NSDQ)
$6.24 USD
-0.08 (-1.27%)
Updated May 3, 2019 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ALPN]
Reports for Purchase
Showing records 1 - 20 ( 156 total )
Industry: Medical - Drugs
Industry: Medical - Drugs
Q1 Financials; Acquisition by VRTX Expected to Close by 2Q:24
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Vertex Steps Up with a Big Check; Alpine Acquired; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Call it ALPN Peak; VRTX to Acquire ALPN for $65/sh; D/G to Neutral
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Translational Data Boost Our Enthusiasm to See What Povetacicept Can Do For Lupus Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Oh the Places Povetacicept Can Go; New Translational Data at SLEuro
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
2023 Results; Povetacicept Program Revs Up With Multiple Upcoming Catalysts
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Industry: Medical - Drugs
Updated RUBY-3 Data at WCN; Increasing PT to $47
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Industry: Medical - Drugs
The Class Gets High Marks; Povetacicept Ahead of the Curve
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Povetacicept Remains Primary Focus as AbbVie Amends Acazicolcept Option Agreement; Price Target Upped to $32
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Drugs
Industry: Medical - Drugs
Acazicolcept Study Cut Short; Sharpening Focus on Povetacicept Opportunities
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Industry: Medical - Drugs
Could 2024 Finally Be Biotech''s Breakthrough Year?
Provider: Wedbush Securities Inc.
Analyst: CHICO L